Description: Beijing Kawin Technology Share-Holding Co., Ltd. engages in the development and production of pharmaceutical products primarily in the areas of liver diseases in China. The company's products include recombinant human interferon alfa-2b injection and compound glycyrrhizin. It provides active pharmaceutical ingredients; clinical research services for biological product development, which include drug substances"fermentation and purification, drug product"formulation, and analytical methods development; and contract manufacturing services. The company also serves customers in Pakistan, Colombia, Philippines, Vietnam, Russia, Cambodia, and others. It has strategic partnership with Legend Capital, Haitong Capital, and Cybernaut. The company was founded in 2008 and is based in Beijing, China.
Home Page: www.kawin.com.cn
Building 3, No. 6, Rongjing East Street
Beijing,
100176
China
Phone:
86 10 6789 2271
Officers
| Name | Title |
|---|---|
| Mr. Desheng Zhou | Gen. Mang. and Chairman |
| Mr. Wei Guo | Chief Financial Officer |
| Mr. Tao Wang | Chief Research Officer |
| Mr. Chongfei He | Deputy Gen. Mang. & Board Sec. and Director |
| Mr. Jifeng Shi | Deputy Gen. Mang. and Director |
| Mr. Jianhua Hou | Director of Beiyi Protein |
| Ms. Dongxia Li | VP of Beiyi Protein |
Exchange: SHG
Country: CN
Currency: Renminbi (¥)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 41.6491 |
| Price-to-Book MRQ: | 2.0494 |
| Price-to-Sales TTM: | 2.7368 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 647 |